Close Menu

People in the News

May 22, 2019

David Fenstermacher

DNAnexus has hired David Fenstermacher as vice president of precision medicine and data services. In this role, Fenstermacher will supervise the vendor's data management products for precision health and drup discovery applications. Fenstermacher, a molecular biologist and informatician, previously was vice president of R&D bioinformatics at MedImmune. He also had been chief research information officer at Virginia Commonwealth University and was founding chair of the Department of Biomedical Informatics at the H. Lee Moffitt Cancer Center.

May 21, 2019

Sangeeta Bhorade

Veracyte has hired Sangeeta Bhorade as medical director of pulmonology to lead medical affairs for the firm's pulmonology products. Bhorade joins Veracyte from Northwestern University Feinberg School of Medicine where she was a professor of medicine and medical director of the lung transplant program. Previously, she was medical director of the lung transplant program at the University of Chicago Medical Center and has also served as associate medical director of lung transplant at Loyola University Chicago.

May 15, 2019

Norman Winarsky

Predictive analytics firm Interpreta has hired Norman Winarsky as vice president of artificial intelligence and natural-language analytics. In that capacity, Winarsky will supervise development of voice, image, and natural-language interpretation technologies for the company. Winarsky, a former president of SRI Ventures, cofounded the Siri voice assistant.

May 13, 2019

Jan Groen

Novigenix has appointed Jan Groen as the firm's CEO and member of its board of directors. Prior to Novigenix, Groen served as president and CEO of MDxHealth. Groen is co-founder of ViroClinics, founder and CEO of DxOrange, and currently serves on the board of Angle and Destina Genomics. 

May 10, 2019

Nancy White

Inagene Diagnostics has appointed Nancy White as its CEO. White joined the firm in January as VP of sales and marketing. Prior to Inagene, White held several management roles at Novartis and Novartis Oncology from 2008 to 2018, including VP and franchise head, retina, region LACan; as well as global team lead, advancing commercial excellence, innovative customer models. Before Novartis, White served in multiple roles at Allergan from 2003 to 2008. Prior to Allergan, she held roles at Eli Lilly from 1999 to 2003. 

May 09, 2019

Sun Kim

Centogene has appointed Sun Kim as its chief strategy and investor relations officer. Prior to Centogene, Kim served as head of corporate strategy at Shire Pharmaceuticals. Before Shire, Kim worked at Alcon for six years, where he served in multiple roles including head of strategy and general manager of Alcon Singapore.

May 08, 2019

Christian Meisel

Molecular Health has appointed Christian Meisel as its chief medical officer. Prior to Molecular Health, Meisel worked at Roche, where he served in multiple leadership roles including global head of its personalized healthcare platform, acting global head of translational medicine oncology, and global head of biomarkers and translational R&D innovation. 

May 07, 2019

David Parker, Mike Evans

David Parker, a general partner in Ampersand Capital Partners, and Mike Evans, operating partner at Ampersand, have joined the board of Dutch firm Genome Diagnostics, which said this week that Ampersand invested an undisclosed amount in the firm. Ampersand, as a result, became minority shareholders in GenDx. 

May 02, 2019

Sue Paish

Contextual Genomics has appointed Sue Paish as the chair of its board of directors. She will be replacing Chris Wagner, who is stepping down but will remain a director. Paish is currently CEO of the Digital Technology Super Cluster, chair of the board of directors of the Business Council of British Columbia, and a director of CORIX Group. Paish joined Contextual Genomics in 2018 and previously served as president and CEO of LifeLabs Medical Laboratory Services. Prior to LifeLabs, Paish served as CEO of Pharmasave and managing partner of Fasken. 

Apr 30, 2019

Brent Satterfield

Co-Diagnostics has announced that Brent Satterfield, one of the firm's directors, has resigned from its board. He will remain as the firm's CSO. 

Apr 30, 2019

Jimmy Lin

Freenome has appointed Cheng-Ho Jimmy Lin, as its chief scientific officer, with responsibilities for scientific strategy, research operations, and growing the company’s scientific team. Prior to joining the private sector, Lin led the intramural clinical genomics program at the National Cancer Institute at the National Institutes of Health. At Johns Hopkins and Washington University in St Louis, he also spearheaded the computational analyses of exome sequencing studies in multiple cancer types.

Lin's most recent role was CSO for oncology at Natera, where he drove the development and launch of that firm's blood-based assays for cancer monitoring residual disease detection. He holds an MD and PhD in cellular and molecular medicine and a Masters in health sciences in bioinformatics from Johns Hopkins School of Medicine.

Apr 30, 2019

Ron McGrath

Inscripta has appointed Ron McGrath as its CFO. McGrath has held various leadership and financial roles in the biotechnology and information technology industries. Prior to Inscripta, McGrath served as VP of finance at Illumina. He also served as chief of staff for the company's operations. Before joining Illumina, McGrath held financial leadership roles at Memec and DJ Orthopedics.

Apr 25, 2019

Alfred Bowie Jr.

Veracyte has named Alfred Bowie Jr. as vice president of corporate and business development where he will lead the company's strategic planning process. Previously, Bowie led strategic planning, corporate development and competitive intelligence at Foundation Medicine, a Roche subsidiary, and served in corporate and business development positions at Tecan Group and Danaher Corporation. He has also worked in management consulting at the Boston Consulting Group.

Apr 25, 2019

Darrin Crisitello, Nigel Beard, Marcel Roche

Mission Bio has appointed three members to its executive team, including Darrin Crisitello as chief commercial officer, Nigel Beard as senior VP of research and development, and Marcel Roche as senior VP of finance and administration. Prior to Mission Bio, Crisitello led global clinical teams at Color Genomics and Natera. Crisitello has over 19 years of experience in commercial leadership and business development in next-generation sequencing, microfluidics, artificial intelligence, and machine learning, Beard has launched more than 50 products and has been an inventor on more than 40 patents. He has previously worked at firms such as GlaxoSmithKline and Life Technologies, as well as startups like Feetz. Prior to Mission Bio, Roche served as VP of finance at Achaogen and at Guardant Health.

Apr 25, 2019

Piet Houwen, Dirk Zimmermann, Hilde Eylenbosch

Biocartis has announced several changes to its management team. The firm has appointed Piet Houwen as its chief operating officer earlier this month. Prior to joining Biocartis, Houwen served as COO at Ablynx. Before Ablynx, he held global roles for Sanofi/Genzyme and Janssen Pharmaceutica (part of Johnson & Johnson family of companies).

Biocartis has also appointed Dirk Zimmermann as its global head pharma collaborations and partnering. Zimmerman will assume the position at the firm in May. Prior to joining Biocartis, Zimmermann held positions at Roche Diagnostics and Qiagen in product development and corporate venturing.

Biocartis has also let go of Hilde Eylenbosch as the firm's chief commercial officer, effective at the end of April. The firm does not have plans to immediately appoint a new CCO, as it will redistribute the tasks to the company's CEO and senior commercial management.

Apr 24, 2019

Andrew Last

Bio-Rad Laboratories has appointed Andrew Last as executive VP and chief operating officer, responsible for all operating functions of the company on a global basis. Last was most recently CCO at Berkeley Lights and prior to that he served as COO at Intrexon. He was executive VP and COO at Affymetrix between 2010 and 2016, and has also previously held senior positions at Becton Dickinson, Applied Biosystems, Incyte Genomics, and Monsanto.

Apr 23, 2019

Bahija Jallal

Guardant Health has appointed Bahija Jallal to its board of directors, effective April 17. Jallal has served as the CEO of Immunocore Limited, a T cell receptor biotechnology company, since January 2019. Prior to that she served as executive VP of AstraZeneca and was president of MedImmune, a subsidiary of AstraZeneca, after holding various other research and development positions at the firm. Jallal is a member of the board of trustees at Johns Hopkins University and of UMB Health Sciences Research Park. She has also served as a past president of the Association for Women in Science.

Apr 23, 2019

Joseph Frendo

Caris Life Sciences announced Joseph Frendo has joined the company as chief operations officer. He was senior vice president of PBM Operations at CVS health. Prior to that, he held various management positions at Medco Health Solutions. In his role at Caris, Frendo will direct technical and clinical staff operations and guide strategies to advance quality and optimize efficiences across the firm, Caris said. 

Apr 23, 2019

Melody Harris

SomaLogic has appointed Melody Harris as the firm's president. Harris joined the firm as its chief legal officer in 2018 from Qualcomm Life. Harris previously served as general counsel at HealthyCircles before it was acquired by Qualcomm. Prior to HealthyCircles, Harris held a variety of executive leadership roles at a consulting firm in the broadcasting space. 

Apr 22, 2019

Richard Wenstrup

Epic Sciences has appointed Richard Wenstrup as its chief medical officer. Wenstrup has served in several clinical leadership roles managing life science companies in the past 25 years. Before Epic, he previously served as CMO for Oxford Immunotec, where he oversaw research and development, product development, regulatory, medical, and clinical affairs. From 2006 to 2017, Wenstrup served as CMO at Myriad Genetics. Prior to Myriad, Wenstrup was a pediatrics professor in human genetics at Cincinnati Children's Hospital Medical Center and professor of biomedical engineering at the University of Cincinnati. 

Apr 18, 2019

Ori Karev

Ori Karev has joined Precipio as chief strategy officer. Karev was formerly CEO of UnitedHealthcare Global, the international division of United Healthcare. He also previously worked for Ernst & Young. An attorney by training, Karev has more than 30 years of experience in the healthcare, insurance, and mobility industries, Precipio said.

Apr 17, 2019

Carsten Ullrich

Centogene has appointed Carsten Ullrich its director of artificial intelligence. He will direct the firm's use of AI to enhance diagnostic effectiveness and quality, and to discover new insights, accelerate biomarker development, and drive solutions for drug firms. Ullrich was most recently associate head of a research lab and senior researcher at the German Research Center for Artifidal Intelligence. 

Apr 16, 2019

Marijn Dekkers

Marijn Dekkers has been named chairman of the board of synthetic biology firm Ginkgo Bioworks. He also will serve as a strategic advisor of the Boston-based company. Dekkers most recently served as CEO of Bayer AG, and prior to that was CEO of Thermo Fisher Scientific. He also currently serves as chairman of Unilever and is founder and chairman of Novalis LifeSciences, a boutique investment and advisory firm.

Apr 15, 2019

James Corbett

PerkinElmer said recently that Executive Vice President and President of Discovery & Analytical Solution James Corbett is leaving the company on April 30. His departure follows a "conversation" between PerkinElmer and Corbett, the company said in a document filed with the US Securities and Exchange Commission. 

Apr 05, 2019

Andrew Brooks

Circuit Clinical, an integrated research organization that facilitates clinical trials and biospecimen collection, has added Andrew Brooks to its board of directors. Brooks is currently chief operating officer of RUCDR Infinite Biologics (RUCDR) at Rutgers University, the world's largest academic biorepository managing biological resources for clients such as the National Institutes of Health, as well as leading academic researchers and major pharmaceutical and biotechnology companies. He is a professor of genetics at Rutgers University and a member of the Human Genetics Institute of New Jersey.

Pages

The American Prospect writes that the pilot program to test the DNA of migrants could lead to more family separations.

An international commission is to develop a report on how researchers, clinicians, and regulators should evaluate the clinical applications of human germline genome editing.

The US Department of Agriculture presents a new blueprint for animal genomic research.

In Genome Research this week: repetitive element deletion linked to altered methylation and more in form of muscular dystrophy; human contamination in draft bacterial and archaeal genomes; and more.